Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RCUS | US
1.26
8.19%
Healthcare
Biotechnology
30/06/2024
04/10/2024
16.65
15.62
16.70
15.51
Arcus Biosciences Inc. a clinical-stage biopharmaceutical company develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab an anti-TIGIT investigational monoclonal antibody which is in Phase 2 and Phase 3 clinical trial; and AB308 an investigational anti-TIGIT monoclonal antibody which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant a dual A2a/A2b adenosine receptor antagonist which is in Phase 2 clinical trial; Quemliclustat a small-molecule CD73 inhibitor which is Phase 1b and Phase 2 clinical trial; Zimberelimab an anti-PD-1 antibody which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521 an oral and small-molecule inhibitor of HIF-2a which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition the company's preclinical pipeline products include AB598 a CD39 antibody; and AB801 a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences Inc. was incorporated in 2015 and is headquartered in Hayward California.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.8%1 month
47.7%3 months
62.7%6 months
55.5%-
-
2.22
0.02
0.01
3.96
1.83
-
-264.00M
1.52B
1.52B
-
-271.80
-
34.50
-41.47
11.90
15.58
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.23
Range1M
3.46
Range3M
5.23
Rel. volume
1.21
Price X volume
10.80M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 18.82 | 1.60B | -3.19% | n/a | 0.26% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 16.41 | 1.49B | -3.24% | n/a | 6.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 3.96 | 0.76 | Expensive |
Ent. to Revenue | 1.83 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.22 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 62.72 | 74.67 | Par |
Debt to Equity | 0.02 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 1.52B | 3.73B | Emerging |